| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 73.12 | -0.17 (-0.23%) | 53.80 - 75.73 | 879.0 thousand (Below Avg) |
Market data as of 4:02PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 72.83 |
|---|---|
| Previous Close | 73.29 |
| Day's Range | 72.80 - 73.29 |
| Market Cap | 177.0B |
| Avg Volume (10 Day) | 1.2M |
| Price/Earnings (Trailing 12 Mo.) | 18.7x |
| Earnings Per Share (Trailing 12 Mo.) | 3.91 |
| Dividend Yield | 2.43 (3.32%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline
PR Newswire - Wednesday 06/12/2013 8:00 AM ET
Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
PR Newswire - Monday 06/03/2013 11:37 AM ET
Agere Augments Leadership with Pharmaceutical Manufacturing and Supply Chain Expert
Business Wire - Wednesday 05/29/2013 10:59 AM ET
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
PR Newswire - Wednesday 05/29/2013 1:21 AM ET
| NVS | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -2.45% | |
| Net Income Growth (1yr) | 10.99% | |
| Total Debt/Equity | 0.31 | |
| LT Debt/Equity | 0.17 | |
| Earnings Yield | 5.35% | |
| Price/Sales | 3.13 |
| Company | Last | Change |
|---|---|---|
| Pfizer Inc | 29.40 | +0.82% |
| Sanofi SA | 54.56 | -0.84% |
| Merck & Co Inc | 47.75 | -0.10% |
| GlaxoSmithKline PLC | 52.47 | -0.51% |
| Johnson & Johnson | 86.36 | +0.85% |
Data is delayed by at least 15 min.